Leukotriene inhibitors are a class of anti-inflammatory drugs that block the production or action of leukotrienes, powerful chemical signals your body releases during allergic reactions and asthma attacks. The most widely prescribed is montelukast (sold as Singulair), a once-daily pill used primarily for asthma and seasonal allergies. Unlike inhaled corticosteroids, which dampen inflammation broadly, leukotriene inhibitors target a specific piece of the inflammatory machinery, and that precision gives them a distinct role in treatment, along with some limitations worth understanding.
What Leukotrienes Do in Your Body
Leukotrienes are lipid molecules produced by immune cells when your body encounters an allergen or irritant. They belong to a family of compounds derived from arachidonic acid, a fatty acid found in cell membranes. Once released, leukotrienes trigger a cascade of effects that make allergic disease miserable: they cause the smooth muscle around your airways to contract, ramp up mucus production, recruit inflammatory cells like eosinophils into tissue, and influence how cytokines (the immune system’s messenger proteins) behave.1Journal of Allergy and Clinical Immunology. The role of leukotrienes in airway inflammation In practical terms, leukotrienes are partly responsible for the wheezing, congestion, and chest tightness of an asthma flare-up, and they help perpetuate the stuffy nose and sneezing of hay fever.
There are two main branches of leukotriene activity that matter for drug design. Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are the molecules behind bronchoconstriction, mucus secretion, and eosinophil recruitment. They were originally identified in the late 1970s as the mysterious “slow-reacting substance of anaphylaxis” that scientists had been chasing for decades.2American Journal of Respiratory and Critical Care Medicine. The Discovery of the Leukotrienes The other branch involves leukotriene B4, which primarily attracts and activates neutrophils and monocytes, amplifying and prolonging tissue inflammation.3PubMed. Leukotriene B4 Current drugs on the market mainly target the cysteinyl leukotriene pathway, though that is slowly changing as researchers explore newer targets.
Two Ways to Block Leukotrienes
Leukotriene inhibitors come in two pharmacological flavors, and understanding the difference matters because they have different side-effect profiles and dosing requirements.
The first and more common approach is to block the receptor that cysteinyl leukotrienes bind to. Drugs like montelukast and zafirlukast sit on the cysLT1 receptor and prevent leukotrienes from docking there. Both have binding affinities roughly twice that of the body’s own leukotriene LTD4, so they outcompete the natural signal effectively.4American Journal of Respiratory and Critical Care Medicine. Pharmacology of Leukotriene Receptor Antagonists These are oral medications, which is one of their main practical advantages over inhalers. Montelukast is taken once daily, usually in the evening, and zafirlukast twice daily.
The second approach is to prevent leukotrienes from being made in the first place. Zileuton does this by inhibiting 5-lipoxygenase, the enzyme that kicks off leukotriene production. Research has shown that zileuton also has some unexpected additional effects: it suppresses certain prostaglandins by interfering with the release of arachidonic acid from cell membranes, an action that appears to be independent of its leukotriene-blocking role.5PubMed Central. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages Zileuton is used far less often than montelukast, partly because it requires dosing four times a day (or twice daily in its extended-release form) and partly because of liver safety concerns covered below.
Asthma and Where These Drugs Fit In
Asthma is the primary reason leukotriene inhibitors exist as a drug class. The question most people have is straightforward: how well do they work compared to inhaled corticosteroids, which are the first-line treatment?
The honest answer is that inhaled corticosteroids are more effective for most people. International guidelines recommend low-dose inhaled corticosteroids as the preferred controller therapy for persistent asthma in both children and adults, with leukotriene receptor antagonists positioned as an alternative.6PubMed Central. Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma In head-to-head comparisons, inhaled steroids tend to produce greater improvements in lung function and overall asthma control.7PubMed. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial
That said, for mild persistent asthma, the gap narrows considerably. One trial found that the percentage of days with good asthma control overlapped by about 98% between montelukast and beclomethasone (a standard inhaled corticosteroid), with both outperforming placebo on measures like asthma attacks and rescue medication use.8PubMed. Effects of montelukast and beclomethasone on airway function and asthma control Montelukast also works well as an add-on to inhaled corticosteroids, improving symptoms and allowing some patients to lower their steroid dose.9PubMed Central. Montelukast in asthma: a review of its efficacy and place in therapy In clinical practice, the combination is common: a patient whose asthma is not fully controlled on a low-dose inhaler may add montelukast rather than increase the steroid dose.
There is a practical wrinkle to keep in mind when stepping down treatment. A pilot trial comparing two step-down strategies in well-controlled asthma found that patients who reduced their inhaled corticosteroid dose (while continuing montelukast) had fewer treatment failures than patients who stopped montelukast entirely (while maintaining their steroid dose).10PubMed Central. Comparison of ICS dose reduction vs. montelukast discontinuation for step-down therapy in well-controlled asthma: a pilot randomized controlled trial The sample was small, but the finding suggests that montelukast’s contribution to asthma control can be underestimated and that pulling it abruptly may destabilize some patients.
Exercise-Induced Bronchoconstriction
If leukotriene inhibitors have a standout niche in asthma care, it is exercise-induced bronchoconstriction (EIB), the chest tightness and breathing difficulty that hits during or after vigorous physical activity. This is one scenario where montelukast genuinely shines.
A landmark trial published in the New England Journal of Medicine demonstrated that montelukast provided meaningful protection against EIB, improving the post-exercise drop in lung function by roughly 47% compared with placebo after 12 weeks of treatment.11PubMed. Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction Protection kicks in fast: studies show benefit within two hours of the first dose and lasting through at least eight hours, with no loss of effectiveness after months of daily use.12PubMed. Time-effect of montelukast on protection against exercise-induced bronchoconstriction That last point matters because long-acting beta-agonists, another common preventive option for EIB, can lose their protective effect over time with regular use. Montelukast does not seem to have that tolerance problem.13PubMed Central. Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist
For athletes, weekend warriors, or children who just want to run around at recess without wheezing, the appeal of a once-daily pill that prevents exercise symptoms without developing tolerance is obvious. It is one of the clearest-cut uses for leukotriene inhibitors.
Allergic Rhinitis
Montelukast also carries an FDA-approved indication for seasonal allergic rhinitis (hay fever), and some doctors prescribe it for patients dealing with both asthma and allergies since one drug addresses both conditions. But the evidence here is less impressive than in asthma.
A systematic review and meta-analysis found that leukotriene receptor antagonists improved daily rhinitis symptom scores by about 5% more than placebo, a modest effect. Antihistamines outperformed them by a small margin, and nasal corticosteroid sprays outperformed them by a larger one, improving symptom scores roughly 12% more than leukotriene antagonists did.14PubMed. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis For someone whose only problem is a stuffy nose in spring, a nasal steroid spray or an antihistamine is the better first choice. Leukotriene inhibitors make more sense for rhinitis when they are already being taken for asthma and the allergy relief is a bonus, or when a patient cannot tolerate nasal sprays.
Early work with zafirlukast confirmed that blocking the leukotriene receptor does reduce nasal congestion, sneezing, and runny nose in seasonal allergies, with effects detectable within hours of the first dose.15American Journal of Respiratory and Critical Care Medicine. The Leukotriene D4-Receptor Antagonist, ICI 204,219, Relieves Symptoms of Acute Seasonal Allergic Rhinitis The mechanism is real, it just is not as strong for nasal symptoms as it is for airway symptoms.
Safety and the Black Box Warning
For years, montelukast was considered one of the safest long-term asthma medications available, which is part of why it became so widely prescribed, especially in children. That reputation took a hit in March 2020, when the FDA placed a black box warning on the drug due to reports of serious neuropsychiatric side effects, including agitation, depression, sleep disturbances, suicidal thoughts, and behavioral changes.16PubMed Central. The Impact of Montelukast’s Black Box Warning on Pediatric Mental Health Adverse Event Reports
A black box warning is the FDA’s most serious alert short of pulling a drug from the market. The agency required that montelukast be reserved for patients who have not responded adequately to other therapies or who cannot tolerate them. In practice, many allergists and pulmonologists still prescribe montelukast, but the conversation with patients has changed. You should know that these neuropsychiatric effects remain relatively uncommon, and most people tolerate the drug well. But if you or your child experiences mood changes, unusual anxiety, difficulty sleeping, or behavioral shifts after starting montelukast, stop the medication and contact your prescriber. The effects typically resolve after discontinuation.
Zileuton carries a different safety concern: liver toxicity. In a 12-month study, about 4.4% of patients on zileuton developed significant elevations in liver enzymes, compared with about 1% of patients receiving usual care alone. Most of these elevations occurred within the first three months of treatment.17PubMed. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma Animal research has shed some light on the mechanism, linking zileuton to nitrosative stress and disrupted lipid balance in the liver, with a genetic component determining susceptibility.18Toxicological Sciences. Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice If you take zileuton, regular liver function testing is standard practice, particularly during the first several months.
Why Some People Respond and Others Don’t
One of the frustrations with leukotriene inhibitors is the variability in response. Some patients experience dramatic improvement; others get almost nothing from the drug. Genetics appears to be a major reason.
Research has focused on variations in genes that encode the enzymes and transporters in the leukotriene pathway. One of the most studied is a repeat polymorphism in the ALOX5 gene, which encodes 5-lipoxygenase. Patients who carry at least one copy of the common five-repeat version of this gene variant tend to respond well to montelukast, experiencing fewer asthma flare-ups and better improvements in lung function. Those carrying two copies of the less common four-repeat variant showed essentially no benefit, with no meaningful reduction in exacerbations and no improvement in lung function after treatment.19Respiratory Medicine. Influence of ALOX-5 promoter polymorphisms on montelukast treatment response in moderate persistent asthma
Other genetic variants matter too. A study looking at multiple genes across the leukotriene pathway found associations between variations in the ALOX5, MRP1, LTC4S, and LTA4H genes and different aspects of montelukast response, including changes in lung function and exacerbation rates.20PubMed Central. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma A meta-analysis of European cohorts found that carriers of a particular variant in the LTA4H gene had nearly three times the odds of experiencing an asthma exacerbation while on montelukast, suggesting the drug simply was not working well enough for them.21PLoS ONE. LTA4H rs2660845 association with montelukast response in early and late-onset asthma
None of this is yet part of routine clinical practice. Your doctor is not going to genotype you before writing a montelukast prescription. The practical consequence is that a trial period is the standard approach: start the drug, give it a few weeks, and assess whether it is helping. If it is not, the genetic explanation is plausible, but the action is the same regardless: try something else.
Children, Adherence, and the Pill Advantage
Montelukast is approved for children as young as six months (in granule form) and is one of the most prescribed asthma medications in pediatrics. A big reason for its popularity, beyond efficacy, is adherence. Getting a young child to properly use an inhaler with a spacer twice a day is genuinely difficult. A chewable tablet at bedtime is easier for everyone.
The numbers bear this out. In a trial comparing montelukast to inhaled cromolyn (another non-steroid controller), 84% of children were highly adherent to the montelukast regimen, versus just 48% with the inhaler.22Current Therapeutic Research. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence A separate study comparing montelukast to inhaled beclomethasone found a similar pattern: about 82% of children on montelukast were highly compliant versus 45% on the inhaler. Parents rated montelukast as more convenient, easier to use, and more likely to be taken as directed.23PubMed. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy
A drug that is slightly less potent but actually gets taken consistently may deliver better real-world results than a stronger drug that sits unused in a drawer. This is the pragmatic argument for montelukast in pediatric asthma, and it is a legitimate one. The black box warning has complicated the conversation, but for many families and clinicians, the benefit-risk calculation still favors montelukast when inhaler adherence is poor and the asthma is mild to moderate.
Leukotrienes Beyond the Lungs and Nose
The leukotriene pathway is not confined to the airways. Leukotrienes are produced wherever inflammation occurs, and researchers have been exploring whether inhibiting them could help in cardiovascular disease, brain disorders, and other conditions.
The cardiovascular connection is particularly intriguing. Leukotrienes have been implicated in the development and progression of atherosclerosis, including early lipid buildup in artery walls, foam cell accumulation, and even plaque rupture, the event that triggers heart attacks and strokes.24PubMed Central. Leukotriene signaling in atherosclerosis and ischemia Leukotriene signaling also appears involved in the tissue damage that follows a heart attack or stroke, when blood supply returns to oxygen-starved tissue. A systematic review noted that leukotrienes are produced in pathological conditions like atherosclerosis, stroke, and myocardial infarction, raising the question of whether existing or novel leukotriene-blocking drugs could reduce cardiovascular risk.25PubMed. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: A systematic review of human clinical trials and in vivo animal studies
On the neurological front, a small case series found that memory-impaired patients reported subjective improvements in memory and recall after taking montelukast, and family members of patients with dementia noted reduced agitation, though no objective memory improvement at the doses used.26PubMed Central. Case Series Using Montelukast in Patients with Memory Loss and Dementia This is very early-stage research, and case series are among the weakest forms of clinical evidence. Still, the biological rationale exists: neuroinflammation driven by leukotrienes could plausibly contribute to cognitive decline, and blocking it might offer some benefit. Larger, controlled trials would be needed before anyone should consider using montelukast for this purpose.
Next-Generation Drug Targets
The existing leukotriene inhibitors have been on the market for over two decades, and the field has not stood still. One of the most actively pursued targets is a protein called FLAP (5-lipoxygenase activating protein), which helps 5-lipoxygenase access its fatty acid substrate. Blocking FLAP shuts down leukotriene production at an even earlier step than zileuton does.
Several FLAP inhibitors are in various stages of development. AZD5718 entered early clinical development aimed specifically at coronary artery disease rather than asthma, testing the hypothesis that reducing leukotriene-driven inflammation in blood vessel walls could help patients with established heart disease.27PubMed. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease Another candidate, AZD6642, was designed with an emphasis on reducing the drug’s fat-solubility to improve its metabolic stability and selectivity.28PubMed. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases Virtual screening efforts have also identified novel chemically diverse FLAP inhibitors that potently block cellular leukotriene production, providing new starting points for drug development.29Journal of Chemical Information and Modeling. Discovery of Novel 5‑Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol
Whether any of these compounds reach pharmacy shelves remains to be seen. Drug development timelines are long, and plenty of promising molecules fail in later-stage trials. But the direction of research suggests that the next generation of leukotriene-targeting therapies may look quite different from the montelukast-and-zileuton duo we have now, potentially extending into cardiovascular and other inflammatory diseases where the current drugs were never tested.